Rapamycin First-in-Human Data Suggests Potential Neuroprotection and Complex Biomarker Shifts in Early Alzheimer's

News
#1

Rap_Alz
Rap_Alz2752×1536 237 KB

A critical translation of preclinical longevity data into human neurodegeneration has materialized in a six-month, single-arm pilot trial evaluating weekly rapamycin administration in patients with early-stage Alzheimer’s disease (AD). Targeting the mechanistic target of rapamycin (mTOR) pathway, which regulates cellular growth and autophagy, this intervention aims to alter the natural trajectory of cognitive and metabolic decline.

The primary finding is an unexpected stabilization of brain glucose metabolism. In typical AD progression, patients exhibit distinct metabolic declines in specific cortical regions. However, following 26 weeks of an intermittent 7 mg oral rapamycin dose, participants demonstrated no significant reduction in [18F]FDG uptake within the prespecified primary regions: the posterior cingulate cortex, precuneus, and temporoparietal lobe. Furthermore, exploratory regional analyses identified significant metabolic increases in the putamen, insula, and anterior cingulate cortex, contradicting the established hypometabolic trajectory of the disease.

Simultaneously, the trial generated highly paradoxical cerebrospinal fluid (CSF) biomarker data. Treatment induced significant elevations in total tau, neurofilament light chain (NfL), and amyloid-beta 40, alongside a numerical increase in amyloid-beta 42. While typically interpreted as an exacerbation of neuroaxonal damage, phosphorylated tau (p-tau) remained largely stable. This resulted in a significantly decreased p-tau/total tau ratio, suggesting the protein efflux may reflect enhanced autophagy-mediated clearance (secretory autophagy) rather than acute neurotoxicity.

The safety profile of weekly rapamycin in this geriatric, cognitively impaired demographic was acceptable. No serious adverse events were recorded; common toxicities were restricted to expected mild gastrointestinal disturbances and aphthous ulcers. Despite the lack of a placebo control, the data establish essential feasibility, target engagement, and safety groundwork for adequately powered, randomized controlled trials to evaluate mTOR inhibition as a disease-modifying strategy in neurodegeneration.

Source:
Pre-print paper: Evaluation of rapamycin as a neuroprotective treatment in Alzheimer’s disease: a six-month single-arm open-label clinical pilot trial
Institution: Karolinska Institutet and Karolinska University Hospital. Country: Stockholm, Sweden. Journal Name: medRxiv.

Related Reading: Rapamycin as a preventive intervention for Alzheimer’s disease in APOE4 carriers: targeting brain metabolic and vascular restoration

2 Likes
#2

Study Design Specifications

  • Type: Clinical Pilot Trial (Single-arm, open-label).
  • Subjects: Human.
  • Condition: Early-stage Alzheimer’s Disease (Mild Cognitive Impairment or mild dementia, amyloid-positive via CSF).
  • Sex: 8 Females, 6 Males.
  • N-number: 14 enrolled, 13 completed treatment.
  • Control Group size: 0.
  • Intervention: Oral rapamycin, 7 mg once weekly for 26 weeks.

Mechanistic Deep Dive

The biological premise of this intervention relies on mTOR inhibition to upregulate macroautophagy, thereby clearing proteotoxic aggregates (amyloid-beta oligomers and hyperphosphorylated tau). The data present a significant mechanistic anomaly:

  1. Metabolic Preservation: The preservation of regional cerebral glucose metabolism strongly implies sustained neuronal viability and synaptic activity. Brain regions highly susceptible to early AD pathology did not exhibit the characteristic functional deterioration. Higher whole-blood trough concentrations of rapamycin (48 hours post-dose) linearly correlated with increased metabolic uptake in the temporoparietal cortex and hippocampus, confirming a dose-dependent neuro-metabolic response.

  2. Secretory Autophagy vs. Toxicity: The sharp increase in CSF structural proteins (total tau, NfL) usually indicates accelerated cell death. However, structural MRI confirmed atrophy rates remained at approximately 1.2% over six months, which is lower than the expected 2% annualized decline in AD, uncoupling the fluid biomarker surge from accelerated physical neurodegeneration. The authors postulate this reflects “secretory autophagy”—the active, mTOR-regulated exocytosis of intracellular debris into the extracellular space and CSF, rather than neuronal rupture.

Novelty

This preprint delivers the longest continuous human dataset (26 weeks) evaluating an intermittent rapamycin dosing protocol for neuroprotection. Crucially, it replicates the highly paradoxical CSF biomarker elevations initially observed in a separate 8-week daily-dosing pilot trial (Gonzales et al.), establishing this biomarker dump as a reproducible pharmacological effect of rapamycin in human neurodegeneration, rather than an isolated artifact.

Critical Limitations

This dataset is significantly compromised by structural design flaws inherent to early-phase pilot testing:

  • Absence of Controls: The single-arm structure completely prevents the isolation of the pharmacological effect from regression to the mean or placebo response.
  • Sample Size: N=13 is radically underpowered for neuroimaging and cognitive outcomes, severely restricting the generalizability of the findings.
  • Severe Baseline Confounders: Baseline CSF samples were drawn during diagnostic workups, on average 8 months prior to trial initiation. During this window, all subjects were placed on cholinesterase inhibitors. Therefore, the pre/post CSF shifts are heavily confounded by the concurrent introduction of standard-of-care pharmacotherapy.
  • Missing Data: The failure of clinical glucose measurement equipment mandated the use of surrogate outcome metrics (SUVR and Ki) rather than the absolute metabolic rate of glucose (MRGlu), introducing quantification uncertainty into the primary outcome
1 Like
#3

Here is the rigorous external verification of the biological and clinical claims made in the study.

Claim 1: Rapamycin inhibits the mechanistic target of rapamycin (mTOR) protein kinase, which regulates cell growth, protein synthesis, and autophagy.

Claim 2: Rapamycin has neuroprotective properties in Alzheimer’s disease, including reversing cognitive deficits, reducing amyloid/tau pathology, and increasing cerebral glucose uptake.

  • External Verification: Verified in the literature. Multiple murine models demonstrate that mTOR inhibition facilitates the clearance of Aβ and tau via autophagy and can restore cognitive function.
  • Translational Gap: High. Data derived from engineered transgenic mouse models frequently fail to replicate the complex pathophysiology, timeline, and progression of sporadic human Alzheimer’s disease.
  • Evidence Level: Level D (Pre-clinical / Animal).
  • Citation: Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy (2023)

Claim 3: An earlier 8-week pilot clinical trial demonstrated that daily rapamycin treatment in Alzheimer’s patients increased CSF biomarkers, including amyloid-beta, p-tau, and neurofilament light chain (NfL).

Claim 4: Natural progression of early-stage Alzheimer’s disease is characterized by progressive declines in regional cerebral glucose metabolism (hypometabolism), typically beginning in the posterior cingulate cortex, precuneus, and temporoparietal lobe.

  • External Verification: Verified. FDG-PET hypometabolism in these specific cortical regions is a highly validated, established biomarker of synaptic dysfunction and disease progression.
  • Evidence Level: Level A (Human Meta-analyses / Systematic Reviews).
  • Citation: Brain FDG PET and the Diagnosis of Dementia (2015)

Claim 5: Alzheimer’s disease typically causes progressive total gray matter volume reductions of approximately 2% annually, with hippocampal volume declining by 4–5% annually.

2 Likes
#4

Preprint, but super exciting! Matt Kaeberlein should be happy, he long since decried the lack of studies of rapamycin and AD. Early days, but I hope more to come. And for dementia in general. There are too few neuroprotective drugs out there, and the population is aging.

1 Like